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Summary
Background:  Circulating  cardiac  troponin  T  is  a  marker  of  cardiomyocyte  injury,  and  predicts
adverse outcomes  in  patients  with  chronic  heart  failure.  However,  the  signiﬁcance  of  highly
sensitive cardiac  troponin  T  (hs-TnT)  in  cardiac  dysfunction  remains  uncertain.  The  purpose  of
this study  is  to  evaluate  the  correlation  between  hs-TnT  and  echocardiographic  parameters  or
natriuretic peptides  in  patients  with  heart  failure.
Methods  and  results:  We  analyzed  283  consecutive  out-  or  in-patients  who  had  B-type  natri-
uretic peptide  (BNP)  ≥20  pg/mL  and  were  examined  by  echocardiography  (mean  age  66.5  ±  13.9
years old;  159  males).  Hs-TnT,  BNP,  N-terminal  pro-BNP  (NT-proBNP),  and  creatinine  levels  were
measured simultaneously.  LVEDD  (left  ventricular  end-diastolic  dimension),  LVEF  (left  ventric-
ular ejection  fraction),  E′,  E/E′,  left  ventricular  (LV)  Tei  index,  and  right  ventricular  (RV)  Tei
index were  determined  with  echocardiography.  The  linear  regression  analyses  demonstrated
that log  hs-TnT  correlated  with  LVEDD  (R  =  0.242,  p  <  0.0001),  LVEF  (R  =  −0.369,  p  <  0.0001),
E′ (R  =  −0.447,  p  <  0.0001),  E/E′ (R  =  0.364,  p  <  0.0001),  LV  Tei  index  (R  =  0.303,  p  <  0.0001),  RV
Tei index  (R  =  0.443,  p  <  0.0001),  and  estimated  glomerular  ﬁltration  rate  (eGFR)  (R  =  −0.489,
p <  0.0001).  Using  multiple  variable  regression  analysis,  log  hs-TnT  independently  correlated
with LVEF,  E/E′,  RV  Tei  index,  and  eGFR.  Furthermore,  log  hs-TnT  signiﬁcantly  correlated  with
log BNP  (R  =  0.567,  p  <  0.0001)  or  log  NT-proBNP  (R  =  0.647,  p  <  0.0001).  Multiple  variable  regres-
sion analysis  demonstrated  that  log  hs-TnT  independently  correlated  with  log  BNP,  age,  and
eGFR, or  with  log  NT-proBNP,  age,  sex,  and  eGFR.
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Conclusions:  The  hs-TnT  correlated  with  cardiac  dysfunction  evaluated  by  echocardiography  and
natriuretic
peptides in  patients  with  heart  failure.  The  elevation  of  hs-TnT  levels  in  heart  failure
may represent  cardiac  dysfunction  due  to  minor  and  ongoing  myocardial  injury.
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were  measured,  and  E/E′ was  calculated  as  the  average  of
the  medial  and  lateral  sites.
The  LV  Tei  index  has  been  reported  to  correlate  with  both© 2012  Japanese  College  of  C
Introduction
Circulating  cardiac  troponin  T  (cTnT)  is  a  very  sensitive
and  speciﬁc  biomarker  of  cardiomyocyte  injury,  and  is  used
as  the  diagnostic  and  prognostic  marker  of  acute  coronary
syndromes  [1—4]. Furthermore,  cTnT  elevations  in  patients
with  heart  failure  have  been  reported,  and  increased  cTnT
levels  have  been  correlated  with  the  severity  and  adverse
outcomes  of  heart  failure  [5—15]. However,  the  elevations
of  cTnT  were  detectable  in  only  a  small  fraction  of  patients
with  stable  chronic  heart  failure  (CHF),  because  previous
studies  used  standard  troponin  T  assays  for  which  the  lower
detection  limit  for  cTnT  was  0.01  ng/mL.  Recently,  the
highly  sensitive  assay  for  cTnT  has  been  developed,  and
made  it  possible  to  measure  concentrations  about  10-fold
lower  than  the  lower  detection  limit  of  the  previous  stan-
dard  assay  [16]. By  the  highly  sensitive  assay,  circulating
cTnT  has  been  detected  in  a  large  population  of  patients
with  heart  failure,  and  provides  prognostic  information  in
patients  with  CHF  at  previously  undetectable  concentrations
[13].
B-type  natriuretic  peptide  (BNP)  and  N-terminal  pro-B-
type  natriuretic  peptide  (NT-proBNP)  are  useful  biomarkers
in  heart  failure  assessment.  Although  BNP  and  NT-proBNP
levels  have  been  shown  to  parallel  the  clinical  severity  of
CHF  and  cardiac  dysfunction  [17], the  signiﬁcance  of  highly
sensitive  cardiac  troponin  T  (hs-TnT)  in  cardiac  dysfunction
evaluated  by  echocardiography  has  not  been  elucidated.
We  hypothesized  that  minor  and  ongoing  myocar-
dial  damage  may  be  detected  by  hs-TnT  in  heart
failure,  and  hs-TnT  levels  may  correlate  with  cardiac  dys-
function  evaluated  by  echocardiography,  BNP  levels,  and
NT-proBNP  levels.  Therefore,  the  purpose  of  this  study  was
to  evaluate  the  correlation  between  hs-TnT  and  echocardio-
graphic  parameters  or  natriuretic  peptides  (BNP,  NT-proBNP)
in  patients  with  heart  failure.
Methods
Study  subjects
We  analyzed  283  consecutive  out-  or  in-patients  who  had
BNP  ≥20  pg/mL  (mean  age  66.5  ±  13.9  years  old;  159  males
and  124  females).  Hs-TnT,  BNP,  NT-proBNP,  and  creatinine
levels  were  measured  simultaneously,  and  patients  were
examined  by  echocardiography  within  three  days  before
or  after  collection  of  blood  samples.  Patients  with  atrial
ﬁbrillation,  hemodialysis,  acute  myocardial  infarction,  or
unstable  angina  pectoris  were  excluded  from  this  study.
The  protocol  used  for  the  present  study  was  approved  by
the  institutional  review  board  of  Kagoshima  University,  and
written  informed  consent  was  given  by  all  subjects.
B
a
mology.  Published  by  Elsevier  Ltd.  All  rights  reserved.
easurement  of  hs-TnT,  BNP,  NT-proBNP,  and
stimated glomerular  ﬁltration  rate
erum  cTnT  concentrations  were  measured  with  hs-
nT  reagents  by  electrochemiluminescence  immunoassay
ECLIA)  with  Elecsys  Troponin  T-High  Sensitive  Immunoas-
ay  (Roche  Diagnostics  Ltd.,  Rotkreuz,  Switzerland),  with
n  analytical  measurement  range  of  0.003—10  ng/mL.  The
alue  at  the  99th  percentile  cutoff  from  a  healthy  ref-
rence  population  (n  =  616)  was  0.014  ng/mL  [16]. The
0%  coefﬁcient  of  variation  concentration  is  reportedly
lose  to  or  less  than  the  99th  percentile  of  the  reference
opulation  [16].
Using the  same  serum  samples,  NT-proBNP  levels  were
easured  by  ECLIA  on  the  Cobas  6000  analyzer  (Roche  Diag-
ostics  Ltd.)  and  creatinine  levels  were  measured  by  an
nzymatic  method.
At  the  same  time,  BNP  concentrations  were  mea-
ured  using  the  EDTA-plasma  samples  by  chemiluminescent
nzyme  immunoassay  on  the  PATHFAST  analyzer  (Mitsubishi
hemical  Medience  Co.,  Tokyo,  Japan).
The  estimated  glomerular  ﬁltration  rate  (eGFR)  was  cal-
ulated  by  the  equation  of  the  Japanese  Society  of  Nephrol-
gy:  eGFR  =  194  ×  Age−0.287 ×  Scr−1.094 (mL/min/1.73  m2),
emales  ×  0.739.
chocardiographic  examination
tandard  two-dimensional  (2D)  and  Doppler  echocardio-
raphic  examinations  were  performed  in  all  subjects  using
—5-MHz  phased  array  transducers  and  commercially  avail-
ble  scanners  (Philips  Medical  Systems  IE33,  Andover,  MA,
SA;  Aloka  SSD-5500,  Tokyo,  Japan;  Vivid  7,  GE  Medi-
al  Systems,  Milwaukee,  WI,  USA).  LVEDD  (left  ventricular
nd-diastolic  dimension),  LVEF  (left  ventricular  ejection
raction),  E′,  E/E′,  left  ventricular  (LV)  Tei  index,  and  right
entricular  (RV)  Tei  index  were  determined  with  echocar-
iography.
LVEDD  was  measured  by  M-mode  echocardiography  and
VEF  was  obtained  using  the  modiﬁed  biplane  Simpson’s
ethod.  The  mitral  ﬂow  velocity  was  recorded  in  the  apical
-chamber  view  by  placing  the  sample  volume  of  the  pulsed
ave  Doppler  echocardiography  at  the  mitral  valve  tip.  The
arly  diastolic  mitral  ﬂow  velocities  (E)  were  measured.  In
ddition,  tissue  Doppler  images  of  the  medial  and  lateral
itral  annulus  were  obtained  from  the  apical  4-chamber
iew.  The  early  diastolic  velocities  of  the  mitral  annulus  (E′)NP  [18]  and  NT-proBNP  [19]  in  patients  with  LV  dysfunction,
nd  it  is  determined  as  follows.  Doppler  time  intervals  were
easured  from  the  LV  inﬂow  and  the  LV  outﬂow  velocities
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LV inflow
(RV inflow) a 
ICT ET IRT
Tei  index 
= (ICT + IRT)  / ET
= (a – b) / b
LV outflow
      
IRT = (c – d) 
b
(RV outflow)
c
ICT = (a – b)  – IRT
ECG
ICT: isovolumic contraction timec
IRT
     
IRT: isovolumic  relaxation  time
ET : ejection  time
d
Figure  1  Scheme  of  the  measurement  of  the  Tei  index,  iso-
volumic contraction  time  (ICT),  ejection  time  (ET),  isovolumic
relaxation  time  (IRT),  and  electrocardiogram  (ECG).  ‘‘a’’,  inter-
val between  the  cessation  and  onset  of  left  ventricular  (LV)
inﬂow,  which  is  the  sum  of  ICT,  ET,  and  IRT;  ‘‘b’’,  LV  ET;  ‘‘c’’,
interval  between  the  R  wave  on  the  ECG  and  onset  of  LV  inﬂow;
‘‘d’’, interval  between  the  R  wave  on  the  ECG  and  cessation
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ivided  by  ET,  was  calculated  as  (a  −b)/b.  RV,  right  ventricular.
s  shown  in  Fig.  1.  The  interval  ‘‘a’’  was  measured  from  the
essation  of  the  LV  inﬂow  to  the  onset  of  the  next  inﬂow.
he  interval  ‘‘b’’,  ejection  time  (ET),  was  measured  from
he  onset  of  the  LV  outﬂow  velocity  to  its  cessation.  The  LV
sovolumic  relaxation  time  (IRT)  was  obtained  by  subtracting
he  interval  ‘‘d’’,  between  the  R  wave  on  the  electrocardio-
ram  and  the  cessation  of  the  LV  outﬂow,  from  the  interval
‘c’’,  between  the  R  wave  and  onset  of  the  LV  inﬂow.  LV  iso-
olumic  contraction  time  (ICT)  was  obtained  by  subtracting
RT  from  (a  −  b).  All  measurements  were  performed  from  3
onsecutive  beats,  and  average  values  were  obtained.  LV
ei  index,  deﬁned  as  the  sum  of  ICT  and  IRT  divided  by
T,  was  calculated  as  (a  −b)/b  [20—22]. In  the  same  way,
V  Tei  index  was  also  calculated  by  Doppler  time  intervals
hich  were  measured  from  the  RV  inﬂow  and  the  RV  outﬂow
elocities.tatistical  analysis
ata  are  expressed  as  the  mean  ±  SD.  The  log-transformed
s-TnT  levels  were  used,  as  the  values  were  not  normally
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igure  2  Histogram  of  highly  sensitive  troponin  T  (hs-TnT)  levels  (A.  Kusumoto  et  al.
istributed  (Fig.  2).  The  same  as  for  hs-TnT,  the  log
ormalization  of  skewed  data  was  used  in  BNP  (log  BNP),  and
T-proBNP  (log  NT-proBNP).  The  relationship  between  con-
inuous  variables  was  analyzed  by  linear  regression  analysis.
he  independence  of  the  association  between  variables,
hich  showed  the  signiﬁcant  correlation  with  log  hs-TnT
y  linear  regression  analyses,  was  tested  with  multiple
egression  analysis.  Non-normally  distributed  variables  were
nalyzed  with  non-parametric  Mann—Whitney  U  test.  Statis-
ical  analyses  were  performed  with  Stat  View,  version  5.0.
-Values  less  than  0.05  were  considered  statistically  signiﬁ-
ant.
esults
linical  characteristics
able  1  shows  the  characteristics  of  the  subjects
nrolled  in  the  present  study.  Mean  hs-TnT  level  was
.023  ±  0.032  ng/mL,  166  (58.7%)  patients  had  a  hs-
nT  level  ≤0.014  ng/mL,  and  279  (98.6%)  patients  had
 hs-TnT  level  ≥0.003  ng/mL.  Mean  eGFR  level  was
5.9  ±  25.4  mL/min/1.73  m2 and  116  (41.0%)  patients
howed  eGFR  <60  mL/min/1.73  m2.
Etiology  of  heart  failure  was  ischemic  heart  disease  in
19  patients  (42.0%),  valvular  heart  disease  in  80  patients
28.3%),  hypertensive  heart  disease  in  26  patients  (9.2%),
ypertrophic  cardiomyopathy  in  17  patients  (6.0%),  dilated
ardiomyopathy  in  15  patients  (5.3%),  and  others  in  26
atients  (9.2%).
orrelation  between  hs-TnT  and  echocardiographic
ndices or  clinical  variables
e  analyzed  the  correlation  between  hs-TnT  and  echocar-
iographic  indices.  The  log  hs-TnT  demonstrated  a  positive
orrelation  with  LVEDD,  E/E′, LV  Tei  index,  and  RV  Tei  index
LVEDD:  R  =  0.242,  p  <  0.0001,  E/E′: R  =  0.364,  p  <  0.0001,  LV
ei  index:  R  =  0.303,  p  <  0.0001,  RV  Tei  index:  R  =  0.443,
 <  0.0001,  Table  2),  and  a  negative  correlation  with  LVEF  and
′ (LVEF:  R  =  −0.369,  p  <  0.0001,  E′: R =  −0.447,  p  <  0.0001,
able  2).
Furthermore,  we  analyzed  whether  hs-TnT  correlated
ith  renal  function  evaluated  with  eGFR  or  correlated
ith  age.  There  was  a  negative  correlation  between
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A)  and  log  hs-TnT  (B).  Black  line  shows  the  normal  distribution.
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Table  1  Subjects’  characteristics  (n  =  283).
Age  (years)  66.5  ±  13.9
Sex (males/females)  159/124
Hemoglobin  (g/dL)  13.1  ±  1.8
Creatinine  (mg/dL) 0.95  ±  0.51
eGFR  (mL/min/1.73  m2)  65.9  ±  25.4
hs-TnT  (ng/mL)  0.023  ±  0.032
BNP (pg/mL)  259.1  ±  489.4
NT-proBNP  (pg/mL)  1084.9  ±  2255.8
Echocardiographic  indices
LVEDD  (mm)  49.1  ±  8.9
LVEF  (%) 58.9  ±  17.6
E′ (cm/s)  6.5  ±  2.7
E/E′ 12.3  ±  6.6
LV Tei  index  0.53  ±  0.22
RV Tei  index  0.36  ±  0.18
Etiology  of  heart  failure
Ischemic  heart  disease  119  (42.0%)
Valvular  heart  disease  80  (28.3%)
HHD 26  (9.2%)
HCM 17  (6.0%)
DCM 15  (5.3%)
Others  26  (9.2%)
NYHA class
I 174  (61.5%)
II 75  (26.5%)
III 26  (9.2%)
IV 8  (2.8%)
Medication
ACE-I/ARB 166  (58.7%)
-Blocker  105  (37.1%)
Loop  diuretic 95  (33.6%)
Spironolactone 54  (19.1%)
eGFR, estimated glomerular ﬁltration rate; hs-TnT, highly sen-
sitive cardiac troponin T; BNP, B-type natriuretic peptide;
NT-proBNP, N-terminal pro-B-type natriuretic peptide; LVEDD,
left ventricular end-diastolic dimension; LVEF, left ventricular
ejection fraction; LV, left ventricular; RV, right ventricular; HHD,
hypertensive heart disease; HCM, hypertrophic cardiomyopathy;
DCM, dilated cardiomyopathy; NYHA, New York Heart Asso-
ciation; ACE-I, angiotensin-converting enzyme inhibitor; ARB,
angiotensin II receptor blocker.
Table  2  Correlation  analysis  of  log  highly  sensitive  cardiac
troponin  T  vs.  echocardiographic  indices,  age,  and  estimated
glomerular  ﬁltration  rate  (eGFR).
Echocardiographic  variables Correlation
coefﬁcient
p-Value
LVEDD 0.242  <0.0001
LVEF −0.369  <0.0001
E′ −0.447  <0.0001
E/E′ 0.364  <0.0001
LV Tei  index  0.303  <0.0001
RV Tei  index  0.443  <0.0001
Age 0.316  <0.0001
eGFR −0.489  <0.0001
LVEDD, left ventricular end-diastolic dimension; LVEF, left
ventricular ejection fraction; LV, left ventricular; RV, right ven-
tricular.
Table  3  Multiple  variable  regression  analysis  between  log
highly  sensitive  cardiac  troponin  T  and  clinical  variables
including  echocardiographic  indices.
p-Value
LVEDD  NS
LVEF 0.0082
E′ NS
E/E′ 0.0010
LV Tei  index  NS
RV Tei  index  0.0049
Age NS
Sex NS
eGFR <0.0001
LVEDD, left ventricular end-diastolic dimension; LVEF, left
ventricular ejection fraction; LV, left ventricular; RV, right ven-
tricular; eGFR, estimated glomerular ﬁltration rate; NS, not
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og  hs-TnT  and  eGFR  (R  =  −0.489,  p  <  0.0001,  Table  2).  The
inear  regression  analysis  demonstrated  that  log  hs-TnT  pos-
tively  correlated  with  age  (R  =  0.316,  p  <  0.0001,  Table  2).
In  addition,  we  analyzed  whether  there  was  a  sig-
iﬁcant  difference  in  hs-TnT  levels  between  men  and
omen.  Mann—Whitney  U  test  showed  that  there  was  a
igniﬁcant  difference  between  men  and  women  (men:
.024  ±  0.034  ng/mL  vs.  women:  0.020  ±  0.030  ng/mL;
 =  0.0284).
Moreover,  we  performed  multiple  variable  regression
nalysis  between  log  hs-TnT  and  other  clinical  variables
ncluding  echocardiographic  parameters  which  showed  the
igniﬁcant  correlation  with  log  hs-TnT  by  linear  regression
nalyses.  As  a  result,  log  hs-TnT  was  independently  corre-
ated  with  LVEF,  E/E′,  RV  Tei  index,  and  eGFR  (Table  3).
orrelation  between  hs-TnT  and  BNP  or  NT-proBNP
e  performed  the  linear  regression  analysis  between  hs-
nT  which  is  a  speciﬁc  and  sensitive  marker  of  myocardial
njury,  and  BNP  or  NT-proBNP  which  is  a  biochemical  marker
f  heart  failure.  As  the  results,  log  hs-TnT  correlated  with
og  BNP  (R  =  0.567,  p  <  0.0001,  Fig.  3A)  or  log  NT-proBNP
R  =  0.647,  p  <  0.0001,  Fig.  3B).  Furthermore,  the  multiple
ariable  regression  analysis  demonstrated  that  log  hs-TnT
as  independently  correlated  with  log  BNP,  age,  and  eGFR
Table  4  Multiple  variable  regression  analysis  between  log
highly  sensitive  cardiac  troponin  T  and  clinical  variables
including  natriuretic  peptides.
Model  1  p-Value  Model  2  p-Value
log  BNP <0.0001 log  NT-proBNP  <0.0001
Age 0.0068 Age 0.0034
Sex NS Sex  0.0117
eGFR <0.0001  eGFR  0.0003
BNP, B-type natriuretic peptide; NT-proBNP, N-terminal pro-B-
type natriuretic peptide; eGFR, estimated glomerular ﬁltration
rate; NS, not signiﬁcant.
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Figure  3  Correlation  between  highly  sensitive  troponin  T  (hs-TnT)  and  B-type  natriuretic  peptide  (BNP)  levels  (A)  or  N-terminal
pro-B-type natriuretic  peptide  (NT-proBNP)  levels  (B).  This  scatter  diagram  demonstrates  the  close  positive  correlation  between
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iog hs-TnT  and  log  BNP  (R  =  0.567,  p  <  0.0001),  or  log  NT-proBNP  
Model  1  in  Table  4),  or  with  log  NT-proBNP,  age,  sex,  and
GFR  (Model  2  in  Table  4).
iscussion
n  the  present  study,  we  analyzed  the  association  between
s-TnT  and  echocardiographic  indices,  and  hs-TnT  was  found
o  be  independently  correlated  with  LVEF,  E/E′,  and  RV  Tei
ndex.  E/E′ has  been  reported  to  be  strongly  correlated  with
ulmonary  capillary  wedge  pressure  and  has  been  used  to
valuate  LV  ﬁlling  pressures  noninvasively  [23]. RV  Tei  index
epresents  a  composite  of  systolic  and  diastolic  RV  function.
herefore,  we  suggest  that  the  elevation  of  hs-TnT  levels
eﬂects  cardiac  dysfunction  in  heart  failure.
In  addition,  we  measured  hs-TnT,  BNP,  and  NT-proBNP
evels  simultaneously,  and  linear  regression  analyses  demon-
trated  that  hs-TnT  correlated  with  both  BNP  and  NT-proBNP.
urthermore,  multiple  variable  regression  analysis  showed
hat  hs-TnT  was  independently  correlated  with  both  BNP
nd  NT-proBNP.  Therefore,  we  suggest  that  for  the  evalu-
tion  of  heart  failure  severity,  hs-TnT  may  be  as  useful  as
he  natriuretic  peptides.
Recently,  Eggers  et  al.  examined  103  stable  patients  with
V  dysfunction  and  found  that  patients  with  higher  hs-TnT
>13.5  ng/L)  had  higher  pulmonary  capillary  wedge  pressure,
ean  right  atrial  pressure,  mean  pulmonary  artery  pres-
ure,  and  pulmonary  vascular  resistance,  but  lower  cardiac
ndex  than  patients  with  lower  hs-TnT  (≤13.5  ng/L)  [24].
owever,  they  did  not  show  a  linear  relationship  between
s-TnT  and  right-heart  hemodynamic  parameters  obtained
y  catheterization.  We,  for  the  ﬁrst  time,  demonstrated  the
ndependent  correlation  between  hs-TnT  and  both  echocar-
iographic  indices  and  natriuretic  peptides.
Shah  et  al.  demonstrated  an  independent  correlation
etween  cTnT  and  LVEDD,  LV  mass  index,  or  E′ in  44  patients
ith  acute  heart  failure  with  preserved  LVEF  [25]. We  also
emonstrated  a  signiﬁcant  negative  correlation  between
og  hs-TnT  and  E′.  Thus,  elevated  hs-TnT  values  may  be  asso-
iated  with  impaired  LV  relaxation.
Tsutamoto  et  al.  reported  that  decreased  renal  clear-
nce  contributes  to  elevated  cTnT  levels  in  CHF  patients
o
l
c
c.647,  p  <  0.0001).
ith  chronic  kidney  disease  [26]. Sato  et  al.  showed  that
s-TnT  independently  correlated  with  eGFR  in  patients  with
reated  essential  hypertension  [27]. We  also  demonstrated
n  independent  correlation  between  hs-TnT  and  eGFR.  Renal
ysfunction  is  one  of  the  factors  that  contribute  to  the  ele-
ation  of  hs-TnT.
Although  the  mechanism  of  myocyte  injury  and  the
elease  of  cTnT  in  CHF  is  not  completely  understood,  several
euroendocrine  systems  (renin—angiotensin—aldosterone,
ympathetic  nerve  activity,  endothelin)  and  inﬂammatory
echanisms  are  chronically  activated  in  patients  with
eart  failure  and  might  contribute  to  myocyte  injury  and
ell  death  progressing  slowly  over  several  years  [28]. In
ddition,  myocardial  stretch  or  toxic  cytokines  were  also
eported  to  induce  myocardial  damage,  such  as  subendo-
ardial  ischemia/necrosis  and  apoptosis  [29—31]. The  highly
ensitive  assay  for  cTnT  has  a  10-fold  lower  detection  limit
ompared  with  the  traditional  cTnT  assay.  Therefore,  the
s-TnT  assay  makes  it  possible  to  detect  minor  and  ongoing
yocardial  damage  in  heart  failure.
Based  on  the  traditional  assay  for  cTnT,  persistently  ele-
ated  cTnT  concentrations  predicted  adverse  outcomes  in
atients  with  dilated  cardiomyopathy  [6].  Furthermore,  in  a
arge  population  of  CHF  patients,  the  hs-TnT  assay  detected
TnT  in  92.0%  of  the  population,  whereas  cTnT  was  detected
n  only  10.4%  using  the  traditional  assay  [13]. Elevated  hs-
nT  had  prognostic  value  in  that  study,  since  they  were
ssociated  with  more  severe  heart  failure  and  a  worse  out-
ome  [13].
Several  studies  reported  the  usefulness  of  the  combined
easurement  of  cTnT  and  natriuretic  peptides  as  a  prognos-
ic  marker  in  CHF  patients.  Combined  elevations  of  cTnT  and
NP  contributed  the  highest  risk  of  death,  cardiac  transplan-
ation  or  hospitalization  in  CHF  patients  [29]. In  addition,
easurements  of  serum  cTnT  and  NT-proBNP  were  reli-
ble  predictors  of  adverse  cardiac  events,  such  as  sudden
r  heart  failure  death,  or  acute  decompensation  requir-
ng  hospitalization  [32]. Natriuretic  peptides  are  markers
f  heart  failure  status  and  reﬂect  cardiac  load  or  circu-
atory  congestion,  whereas  cTnT  is  a  marker  of  ongoing
ardiomyocyte  injury  in  heart  failure  [32]. Therefore,  the
ombined  measurement  of  hs-TnT  and  natriuretic  peptides
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[Highly  sensitive  cardiac  troponin  T  and  cardiac  dysfunction  
should  provide  more  prognostic  information  than  the  mea-
surement  of  either  biomarker  alone  in  CHF  patients.
Study  limitations
This  study  has  several  limitations.  First,  this  study  enrolled
a  relatively  small  number  of  patients  at  a  single  insti-
tution,  and  additional  studies  in  a  larger  population  at
several  institutions  should  be  conducted.  Second,  patients
with  undiagnosed  coronary  artery  disease  may  have  been
included  among  patients  with  increased  hs-TnT  levels,
because  coronary  angiography  was  not  routinely  per-
formed.  Third,  we  excluded  patients  with  atrial  ﬁbrillation,
hemodialysis,  acute  myocardial  infarction,  and  unstable
angina  pectoris,  so  we  could  not  evaluate  the  relationship
between  hs-TnT  and  cardiac  dysfunction  in  these  patients.
Finally,  we  could  not  distinguish  between  acute  and  chronic
heart  failure  in  this  study.
Conclusions
In  patients  with  heart  failure,  hs-TnT  correlated  with  cardiac
dysfunction  evaluated  by  echocardiography  and  natriuretic
peptides.  The  elevation  of  hs-TnT  levels  in  heart  failure
may  represent  cardiac  dysfunction  due  to  minor  and  ongoing
myocardial  injury.
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